Immunotherapy of non-Hodgkin’s lymphoma with a defined ratio of CD8 + and CD4 + CD19-specific chimeric antigen receptor–modified T cells
Open accessThe DOI matches its Crossref record; 38 of the 38 references it cites were found in a registry or an index.
Abstract
CD19-specific chimeric antigen receptor (CAR)-modified T cells have antitumor activity in B cell malignancies, but factors that affect toxicity and efficacy have been difficult to define because of differences in lymphodepletion and heterogeneity of CAR-T cells administered to individual patients. We conducted a clinical trial in which CD19 CAR-T cells were manufactured from defined T cell subsets and administered in a 1:1 CD4(+)/CD8(+) ratio of CAR-T cells to 32 adults with relapsed and/or refractory B cell non-Hodgkin's lymphoma after cyclophosphamide (Cy)-based lymphodepletion chemotherapy with or without fludarabine (Flu). Patients who received Cy/Flu lymphodepletion had increased CAR-T cell expansion and persistence, and higher response rates [50% complete remission (CR), 72% overall response rate (ORR)] than patients who received Cy-based lymphodepletion without Flu (8% CR, 50% ORR). The CR rate in patients treated with Cy/Flu at the maximally tolerated dose was 64% (82% ORR; n = 11). Cy/Flu minimized the effects of an immune response to the murine single-chain variable fragment component of the CAR, which limited CAR-T cell expansion and clinical efficacy in patients who received Cy-based lymphodepletion without Flu. Severe cytokine release syndrome (sCRS) and grade ≥3 neurotoxicity were observed in 13 and 28% of all patients, respectively. Serum biomarkers, one day after CAR-T cell infusion, correlated with subsequent sCRS and neurotoxicity. Immunotherapy with CD19 CAR-T cells in a defined CD4(+)/CD8(+) ratio allowed identification of correlative factors for CAR-T cell expansion, persistence, and toxicity, and facilitated optimization of lymphodepletion that improved disease response and overall and progression-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“prolonged in vivo persistence of CAR-T cells has been correlated with the depth and durability of clinical responses [32, 36].”
From Harmonisation of quality control tests for academic production of CAR-T cells: a position paper from the WP-bioproduction of the UNITC consortium (2025) · cites this paper as [36]
In the citing paper
“It is also known that lymphodepletion and the establishment of an optimal homeostatic cytokine environment is critical for robust CAR T-cell expansion and function.4,44,45”
From Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma (2021) · cites this paper as [44]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E., & Lister, T. A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.8800 · Cited by 5,715
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Maude, S. L., Frey, N., Shaw, P. A., Aplenc, R., Barrett, D. M., Bunin, N. J., Chew, A., Gonzalez, V. E., Zheng, Z., Lacey, S. F., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1407222 · Cited by 5,413
Chimeric antigen receptor–modified T cells in chronic lymphoid leukemia
Porter, D. L., Levine, B. L., Kalos, M., Bagg, A., & June, C. H. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103849 · Cited by 3,565
Lee, D. W., Kochenderfer, J. N., Stetler-Stevenson, M., Cui, Y. K., Delbrook, C., Feldman, S. A., Fry, T. J., Orentas, R., Sabatino, M., Shah, N. N., et al. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61403-3 · Cited by 2,898
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
A note on quantifying follow-up in studies of failure time
Schemper, M., & Smith, T. L. (1996) · Controlled Clinical Trials · doi:10.1016/0197-2456(96)00075-x · Cited by 2,575
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Riviere, I., Wang, X., Bartido, S., Park, J., Curran, K., Chung, S. S., Stefanski, J., Borquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,476
Kalos, M., Levine, B. L., Porter, D. L., Katz, S., Grupp, S. A., Bagg, A., & June, C. H. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002842 · Cited by 2,388
Appio, L., Landoni, C., La Targia, M., Bertolli, V., Chiarucci, M., Crovetti, G., Vassenna, E., Serio, G., & Bregni, M. (2017) · Chemotherapy · doi:10.1159/000458147 · Cited by 2,327
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Turtle, C. J., Hanafi, L.-A., Berger, C., Gooley, T. A., Cherian, S., Hudecek, M., Sommermeyer, D., Melville, K., Pender, B., Budiarto, T. M., et al. (2016) · Journal of Clinical Investigation · doi:10.1172/jci85309 · Cited by 2,112 · cited 3×
“We observed that treatment with the same lymphodepletion and CD19 CAR-T cell immunotherapy regimen resulted in lower CR rates in NHL and chronic lymphocytic leukemia (CLL) patients compared to B-ALL patients (1, 25).”
BackgroundResultSelf-citation
Research works printed but not linked: 2
- Gordis L Epidemiology 4 Philadelphia Saunders 2008
- Yeh ST Using trapezoidal rule for the area under a curve calculation Proceedings of the Twenty-Seventh Annual SAS User Group International (SUGI) Conference. Paper 229–27 2002
Cited by
Items 401–500 of 999
Song, F., Hu, Y., Zhang, Y., Zhang, M., Yang, T., Wu, W., Huang, S., Xu, H., Chang, A. H., Huang, H., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005701 · Cited by 38
Making drugs from T cells: The quantitative pharmacology of engineered T cell therapeutics
Kirouac, D. C., Zmurchok, C., & Morris, D. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00355-3 · Cited by 45
Novel Immunotherapies for Multiple Myeloma
D’Agostino, M., Boccadoro, M., & Smith, E. L. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0397-7 · Cited by 36
Immunotherapy: A Novel Era of Promising Treatments for Multiple Myeloma
Castellà, M., de Larrea, C. F., & Martín-Antonio, B. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19113613 · Cited by 41
Jiang, H., Hu, Y., & Mei, H. (2020) · Biomarker Research · doi:10.1186/s40364-020-00247-8 · Cited by 40
“Delay or abrogation of an immune response against the murine single-chain variable fragment component of the CAR, increased levels of cytokines that support T cell proliferation and survival, and IDO downregulation in tumor cells may contribute to the enhanced antitumor activity of CAR T cells after strong lymphodeple…”
BackgroundPreclinical development of CD126 CAR-T cells with broad antitumor activity
Mishra, A. K., Kemler, I., & Dingli, D. (2021) · Blood Cancer Journal · doi:10.1038/s41408-020-00405-z · Cited by 36
Time 2EVOLVE: predicting efficacy of engineered T-cells – how far is the bench from the bedside?
Guedan, S., Luu, M., Ammar, D., Barbao, P., Bonini, C., Bousso, P., Buchholz, C. J., Casucci, M., Angelis, B. D., Donnadieu, E., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003487 · Cited by 38
Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality
Smith, R. M., & Shen, R. R. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04372-4 · Cited by 46
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and –γ
Chandrasekaran, S., Funk, C. R., Kleber, T. J., Paulos, C. M., Shanmugam, M., & Waller, E. K. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.718621 · Cited by 38
Ong, S. Y., Pak, S., Mei, M. G., Wang, Y., Popplewell, L. L., Baird, J. H., Herrera, A. F., Shouse, G., Nikolaenko, L., Zain, J. M., et al. (2023) · American Journal of Hematology · doi:10.1002/ajh.27069 · Cited by 37
“1 Fludarabine has been associated with improved CAR T-cell expansion and better clinical outcomes when combined with cyclophosphamide, 2,3 but can lead to neurotoxicity and delayed immune reconstitution.”
Metelo, A. M., Jóźwik, A., Luong, L. A., Dominey-Foy, D., Graham, C., Attwood, C., Inam, S., Dunlop, A. S., Sanchez, K., Cuthill, K., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-21-0157 · Cited by 35
Obarorakpor, N., Patel, D., Boyarov, R., Amarsaikhan, N., Cepeda, J. R., Eastes, D., Robertson, S., Johnson, T. S., Yang, K., Tang, Q., et al. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1207108 · Cited by 38
“Engineered CAR-T cells have been successfully used in cancer treatments (26, 27).”
Targeting the mevalonate or Wnt pathways to overcome CAR T-cell resistance in TP53-mutant AML cells
Mueller, J., Schimmer, R. R., Koch, C., Schneiter, F., Fullin, J., Lysenko, V., Pellegrino, C. E., Klemm, N., Russkamp, N. F., Myburgh, R., et al. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00024-2 · Cited by 38
“…malignancies and multiple myeloma, and that could be an attractive option for TP53 -mutant AML/MDS as well (Berdeja et al, 2021; Davila et al, 2014; Kochenderfer et al, 2015; Lee et al, 2015a; Maude et al, 2014; Munshi et al, 2021; Neelapu et al, 2017; Schuster et al, 2019; Turtle et al, 2016a).”
BackgroundResultCART Cell Toxicities: New Insight into Mechanisms and Management
Zahid, A., Siegler, E. L., & Kenderian, S. S. (2020) · Clinical Hematology International · doi:10.2991/chi.k.201108.001 · Cited by 41
“also demonstrated improved CART cell persistence [44,45] Careful adjustment of the CART cell dose infused in patients with greater disease burden or with extensive preconditioning may reduce toxicities associated with CART cell therapy [46].”
BackgroundShao, M., Yu, Q., Teng, X., Guo, X., Wei, G., Xu, H., Cui, J., Chang, A. H., Hu, Y., & Huang, H. (2021) · Bone Marrow Transplantation · doi:10.1038/s41409-021-01226-9 · Cited by 40
Kozani, P. S., Kozani, P. S., & Rahbarizadeh, F. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.765097 · Cited by 39
Nanomaterials to improve cancer immunotherapy based on ex vivo engineered T cells and NK cells
Han, B., Song, Y., Park, J., & Doh, J. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.01.049 · Cited by 33
Caballero, A. C., Escribà-García, L., Álvarez‐Fernández, C., & Briones, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904497 · Cited by 41
“Several studies in animal models of cancer have shown that TCM cells have a superior antitumor effect than differentiated TEM and TEF cells (64).”
BackgroundMethodInfluentialBerger, S. C., Fehse, B., Akyüz, N., Geffken, M., Wolschke, C., Janson, D., Gagelmann, N., Luther, M., Wichmann, D., Frenzel, C., et al. (2022) · Haematologica · doi:10.3324/haematol.2022.281110 · Cited by 36
Haydu, J. E., & Abramson, J. S. (2024) · Blood Advances · doi:10.1182/bloodadvances.2021004535 · Cited by 43
A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies
Valton, J., Guyot, V., Boldajipour, B. A., Sommer, C., Pertel, T., Juillerat, A., Duclert, A., Sasu, B. J., Duchateau, P. N., & Poirot, L. (2018) · Scientific Reports · doi:10.1038/s41598-018-27264-w · Cited by 36
New developments in immunotherapy for lymphoma
Heyman, B. M., & Yiping, Y. (2018) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2018.0037 · Cited by 40
Eyles, J. E., Vessillier, S., Jones, A., Stacey, G., Schneider, C. K., & Price, J. (2018) · Journal of Chemical Technology & Biotechnology · doi:10.1002/jctb.5829 · Cited by 35
Bouziana, S. D., & Bouzianas, D. G. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.04.003 · Cited by 34
Future of CAR T cells in multiple myeloma
Wudhikarn, K., Mailankody, S., & Smith, E. L. (2020) · Hematology · doi:10.1182/hematology.2020000111 · Cited by 36
A single-chain antibody generation system yielding CAR-T cells with superior antitumor function
Ochi, T., Maruta, M., Tanimoto, K., Kondo, F., Yamamoto, T., Kurata, M., Fujiwara, H., Masumoto, J., Takenaka, K., & Yasukawa, M. (2021) · Communications Biology · doi:10.1038/s42003-021-01791-1 · Cited by 37
A Systematic Review of the Efforts and Hindrances of Modeling and Simulation of CAR T-cell Therapy
Nukala, U., Messan, M. R., Yogurtcu, O. N., Wang, X., & Yang, H. (2021) · The AAPS Journal · doi:10.1208/s12248-021-00579-9 · Cited by 40
“Moreover, infused T-cells are heterogeneous in phenotype, unlike small drug molecules and the optimally effective and safe dose might vary depending on the CAR T-cell phenotype composition (61), lymphodepletion chemotherapy (62, 63), baseline tumor burden (46, 64), and disease type (48).”
BackgroundInfluentialMultifaceted Interplay between Hormones, Growth Factors and Hypoxia in the Tumor Microenvironment
Lappano, R., Todd, L. A., Stanic, M., Cai, Q., Maggiolini, M., Marincola, F., & Pietrobon, V. (2022) · Cancers · doi:10.3390/cancers14030539 · Cited by 32
Analysis of causes for poor persistence of CAR-T cell therapy in vivo
Kong, Y., Tang, L. Y., You, Y., Li, Q., & Zhu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1063454 · Cited by 40
“3 Proportion of CD4+ T cells and CD8+ T cells in injected CAR-T cells The ratio of CD4+ and CD8+ T cells is highly variable in patients with B-ALL and NHL, and studies have shown that the injection a 1:1 ratio of CD4 to CD8 CAR-T cells can ameliorate this phenomenon, resulting in predictable polyclonal proliferation o…”
BackgroundAllogeneic off-the-shelf CAR T-cell therapy for relapsed or refractory B-cell malignancies
Shahid, S., Prockop, S. E., Flynn, G. C., Mauguen, A., White, C., Bieler, J., McAvoy, D. P., Hosszu, K., Cancio, M., Jakubowski, A. A., et al. (2025) · Blood Advances · doi:10.1182/bloodadvances.2024015157 · Cited by 41
Metabolic reprogramming of CAR T cells: a new frontier in cancer immunotherapy
Frlic, T., & Pavlin, M. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1688995 · Cited by 39
Mirzaei, H. R., Mirzaei, H., Namdar, A., Rahmati, M., Till, B. G., & Hadjati, J. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27519 · Cited by 33
“Maude, Frey et al., 2014; Ramos et al., 2015; Till et al., 2008, 2012; Turtle et al., 2016a, 2016b).”
CAR T Cell Therapy Progress and Challenges for Solid Tumors
Stern, L. A., Jönsson, V. D., & Priceman, S. J. (2020) · Cancer treatment and research · doi:10.1007/978-3-030-38862-1_11 · Cited by 35
Chimeric antigen receptor T‐cell therapy toxicities
Greenbaum, U., Kebriaei, P., Srour, S. A., Olson, A. L., Bashir, Q., Neelapu, S. S., Rezvani, K., & Shpall, E. J. (2020) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14403 · Cited by 33
Rath, J. A., Bajwa, G., Carrères, B. M., Hoyer, E. A., Gruber, I., Martinez-Paniagua, M. A., Yu, Y.-R., Nouraee, N., Sadeghi, F., Wu, M., et al. (2020) · Science Advances · doi:10.1126/sciadv.aaz7809 · Cited by 30
In vivo CART cell imaging: Paving the way for success in CART cell therapy
Sakemura, R. L., Can, İ., Siegler, E. L., & Kenderian, S. S. (2021) · Molecular Therapy — Oncolytics · doi:10.1016/j.omto.2021.03.003 · Cited by 33
Efficace, F., Cannella, L., Sparano, F., Giesinger, J. M., Vignetti, M., Baron, F., Bruera, E. D., Luppi, M., & Platzbecker, U. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000802 · Cited by 35
Immune Checkpoint Blockade in Breast Cancer Therapy
Bu, X., Yao, Y., & Li, X. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-981-10-6020-5_18 · Cited by 36
The Landscape of CAR T Cells Beyond Acute Lymphoblastic Leukemia for Pediatric Solid Tumors
DeRenzo, C. C., Krenciute, G., & Gottschalk, S. M. (2018) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_200773 · Cited by 40
Mody, H. R., Ogasawara, K., Zhu, X., Miles, D., Shastri, P. N., Gokemeijer, J., Liao, M. Z., Kasichayanula, S., Yang, T., Chemuturi, N. V., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2986 · Cited by 36
Adoptive Immunotherapy with Antigen-Specific T Cells Expressing a Native TCR
Leung, W. K., & Heslop, H. E. (2019) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0888 · Cited by 31
“Components of the TME can block the activity of immunostimulatory cytokines that are essential for preserving the optimal activity of T cells.”
BackgroundBishop, D. C., Caproni, L. J., Gowrishankar, K., Łęgiewicz, M., Karbowniczek, K., Tite, J. P., Gottlieb, D. J., & Micklethwaite, K. P. (2020) · Molecular Therapy — Methods & Clinical Development · doi:10.1016/j.omtm.2019.12.020 · Cited by 33
A novel full-human CD22-CAR T cell therapy with potent activity against CD22low B-ALL
Tan, Y., Cai, H., Li, C., Deng, B., Song, W., Ling, Z., Hu, G., Yang, Y., Niu, P., Meng, G., et al. (2021) · Blood Cancer Journal · doi:10.1038/s41408-021-00465-9 · Cited by 35
Therapeutic Targeting of Mesothelin with Chimeric Antigen Receptor T Cells in Acute Myeloid Leukemia
Le, Q., Castro, S., Tang, T. T., Loeb, A. M., Hylkema, T., McKay, C. N., Perkins, L., Srivastava, S., Call, L., Smith, J. L., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-1546 · Cited by 34
“MSLN CAR with a short IgG4 hinge domain confers superior cytotoxicity over intermediate and long IgG4 domains To evaluate the therapeutic potential of targeting MSLN, we generated MSLN-directed CARs by fusing the single-chain variable fragment derived from the SS1P immunotoxin (13) to the IgG4 spacer, CD28 transmembra…”
BackgroundOwen, K., Ghaly, R., Shohdy, K. S., & Thistlethwaite, F. C. (2022) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-022-03287-1 · Cited by 35
Evolving CAR-T-Cell Therapy for Cancer Treatment: From Scientific Discovery to Cures
Majumder, A. (2023) · Cancers · doi:10.3390/cancers16010039 · Cited by 41
“There are different factors that contribute to severe toxicities associated with CAR-T-cell therapy, which include disease burden [46], high-dose chemotherapy regimen [47], high-dose CAR-T-cell infusion [48], and peak levels of serum cytokines and C-reactive protein [49].”
BackgroundChimeric Antigen Receptor–Engineered T Cell Therapy in Lymphoma
Strati, P., & Neelapu, S. S. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0789-z · Cited by 30
Nonviral gene delivery to T cells with Lipofectamine LTX
Harris, E., Zimmerman, D., Warga, E., Bamezai, A. K., & Elmer, J. J. (2021) · Biotechnology and Bioengineering · doi:10.1002/bit.27686 · Cited by 32
“Indeed, other groups have previously shown that the time between these two steps significantly impacts gene delivery with viruses, electroporation, and cationic polymers (Levine et al., 2017; Olden et al., 2018; Paludan & Bowie, 2006; Vannucci et al., 2013; Zhang et al., 2018).”
BackgroundMakita, S., Yamamoto, G., Maruyama, D., Asano‐Mori, Y., Kaji, D., Ananthakrishnan, R., Ogasawara, K., Stepan, L. P., Schusterbauer, C., Rettby, N., et al. (2022) · Cancer Medicine · doi:10.1002/cam4.4820 · Cited by 31
Asiry, S., Kim, G., Filippou, P. S., Sanchez, L. R., Entenberg, D. R., Marks, D. K., Oktay, M. H., & Karagiannis, G. S. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.654877 · Cited by 31
Banking on virus-specific T cells to fulfill the need for off-the-shelf cell therapies
Quach, D. H., Lulla, P., & Rooney, C. M. (2022) · Blood · doi:10.1182/blood.2022016202 · Cited by 31
Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma
Li, C., Zhou, F., Wang, J., Chang, Q., Du, M., Luo, W., Zhang, Y., Xu, J., Tang, L., Jiang, H., et al. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01402-y · Cited by 36
“ET019003 cells utilized a fully human anti-CD19 antibody to lessen immunogenic responses that were observed as adverse factors of CAR-T cell kinetics with murine-derived antibodies [25, 26].”
BackgroundPreclinical Optimization of a CD20-specific Chimeric Antigen Receptor Vector and Culture Conditions
Lee, S. Y., Olsen, P., Lee, D. H., Kenoyer, A. L., Budde, L. E., O’Steen, S., Green, D. J., Heimfeld, S., Jensen, M. C., Riddell, S. R., et al. (2017) · Journal of Immunotherapy · doi:10.1097/cji.0000000000000199 · Cited by 30
Modeling cytokine release syndrome
Rooney, C. M., & Sauer, T. (2018) · Nature Medicine · doi:10.1038/s41591-018-0068-9 · Cited by 30
Selective refueling of CAR T cells using ADA1 and CD26 boosts antitumor immunity
Hu, Y., Sarkar, A., Song, K., Michael, S., Höök, M., Wang, R., Heczey, A., & Song, X. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101530 · Cited by 39
Rataj, F., Kraus, F. B. T., Chaloupka, M., Grassmann, S. A., Heise, C., Cadilha, B. L., Duewell, P., Endres, S., & Kobold, S. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01955 · Cited by 31
“Interestingly, this effect was dependent on an optimal CD4+ to CD8+ T cell ratio, which is also in line with clinical observations observed with CAR T cells (7, 8).”
ResultHu, W., Huang, X., Huang, X., Chen, W., Hao, L.-D., & Chen, Z. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109333 · Cited by 30
Antibody‐Based CAR T Cells Produced by Lentiviral Transduction
Prommersberger, S., Hudecek, M., & Nerreter, T. (2020) · Current Protocols in Immunology · doi:10.1002/cpim.93 · Cited by 32
CAR-T cell persistence in the treatment of leukemia and lymphoma
Gupta, A., & Gill, S. I. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1913146 · Cited by 31
“Severe cytokine release syndrome (CRS) requiring intervention with tocilizumab and/or corticosteroids occurred only in patients who had received Flu/Cy conditioning, and patients receiving Flu/Cy were also more likely to develop severe neurotoxicity after CAR-T infusion [64].”
BackgroundXiao, X., Wang, Y., Zou, Z., Yang, Y., Wang, X., Xin, X., Tu, S., & Li, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.954235 · Cited by 33
“(2018) (57) B-ALL 17 CD19 OS (2y): allo-HSCT (17): 33%; non-HSCT (36): 45% (P=0.”
BackgroundButt, O. H., Zhou, A. Y., Ances, B. M., DiPersio, J. F., & Ghobadi, A. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1110647 · Cited by 33
“NOT LDH Wang et al. (9) 68 65 Brexu-cel CD19-CD28-CD28/CD3ζ - CAR T expansion/peak Peak IL-1RA Peak IL-2 Peak IL-6 Peak IL-10 Peak IL-12p40 Peak TNF Peak GM-CSF Peak IFN-γ Peak CCL13 Peak CCL4 Peak GranzymeB Peak CSF CRP Peak CSF IL-6 Peak CSF IL-8 Peak CSF VCAM-1 Schuster et al. (4) 115 56 Tasi-cel CD19-CD8α-4-1BB/CD…”
BackgroundInfluentialTeoh, J. J., & Brown, L. F. (2022) · Cytotherapy · doi:10.1016/j.jcyt.2022.03.013 · Cited by 30
Liu, W., Liu, W., Zou, H., Chen, L. P., Huang, W., Lv, R., Xu, Y., Liu, H., Shi, Y., Wang, K., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008857 · Cited by 35
Overview of infectious complications among CAR T- cell therapy recipients
Arya, S., & Shahid, Z. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1398078 · Cited by 34
Chimeric antigen receptor (CAR) T-cell therapy: Engineering immune cells to treat liver diseases
Jaeckel, E., Friedman, S. L., Hudecek, M., & Protzer, U. (2025) · Journal of Hepatology · doi:10.1016/j.jhep.2025.06.007 · Cited by 32
Yakoub‐Agha, I., Ferrand, C., Chalandon, Y., Ballot, C., Castilla‐Llorente, C., Deschamps, M., Gauthier, J., Labalette, M., Larghero, J., Maheux, C., et al. (2017) · Bulletin du Cancer · doi:10.1016/j.bulcan.2017.10.017 · Cited by 30
Chimeric antigen receptor modified T cell therapy in B cell non‐Hodgkin lymphomas
Levin, A., & Shah, N. N. (2019) · American Journal of Hematology · doi:10.1002/ajh.25403 · Cited by 31
Chicaybam, L., Abdo, L. D. M., Carneiro, M., Peixoto, B., Viegas, M. S., de Sousa, P., Fornazin, M. C., Spago, M. C., Laranjeira, A. B. A., de Campos-Lima, P. O., et al. (2019) · Human Gene Therapy · doi:10.1089/hum.2018.218 · Cited by 29
“24 However, it is currently unknown how different protocols for the generation and expansion of T cells modulate these parameters and the extension of the impact of such differences on the immune response.”
Transient Lentiviral Vector Production Using a Packed-Bed Bioreactor System
McCarron, A., Donnelley, M., McIntyre, C., & Parsons, D. (2019) · Human Gene Therapy Methods · doi:10.1089/hgtb.2019.038 · Cited by 29
Cartron, G., Fox, C. P., Liu, F., Kostić, A., Hasskarl, J., Li, D., Bonner, A., Zhang, Y., Maloney, D. G., & Kuruvilla, J. G. (2022) · Experimental Hematology and Oncology · doi:10.1186/s40164-022-00268-z · Cited by 27
A novel polymer-conjugated human IL-15 improves efficacy of CD19-targeted CAR T-cell immunotherapy
Hirayama, A. V. V., Chou, C. K., Miyazaki, T., Steinmetz, R. N., Di, H. A., Fräßle, S. P., Gauthier, J., Fiorenza, S., Hawkins, R. M., Overwijk, W. W., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022008697 · Cited by 28
“Materials and methods Analyses of clinical trial samples Serum IL-15 concentrations (Luminex Corporation) and CAR T-cell persistence (quantitative reverse transcription polymerase chain reaction; FlapEF1α copies per μg DNA) were analyzed in 190 patients with R/R B-cell malignancies treated in a phase 1/2 clinical tria…”
Safety switch optimization enhances antibody-mediated elimination of CAR T cells
Shabaneh, T. B., Moffett, H. F., Stull, S. M., Derezes, T., Tait, L. J., Park, S., Riddell, S., & Lajoie, M. J. (2022) · Frontiers in Molecular Medicine · doi:10.3389/fmmed.2022.1026474 · Cited by 32
Maurer, K., Grabski, I. N., Houot, R., Gohil, S. H., Miura, S., Redd, R. A., Lyu, H., Lu, W. S., Arihara, Y., Budka, J. A., et al. (2024) · Blood · doi:10.1182/blood.2024024381 · Cited by 33
van de Donk, N. W. C. J., Moreau, P., Miguel, J. F. S., Mateos, M., Dimopoulos, M. A., Zweegman, S., Gay, F., Engelhardt, M. M., Mina, R., Zamagni, E., et al. (2025) · The Lancet Haematology · doi:10.1016/s2352-3026(25)00117-6 · Cited by 33
CARs and other T cell therapies for MM: The clinical experience
Danhof, S., Hudecek, M., & Smith, E. L. (2018) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2018.03.002 · Cited by 29
Wang, L., Gong, W., Wang, S., Neuber, B., Sellner, L., Schubert, M., Hückelhoven‐Krauss, A., Kunz, A. B., Gern, U., MICHELS, B., et al. (2019) · Cytotherapy · doi:10.1016/j.jcyt.2019.02.013 · Cited by 31
Neurological Complications of CAR T Cell Therapy
Landry, K. K., & Thomas, A. A. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00935-6 · Cited by 27
Davey, A. S., Call, M. E., & Call, M. J. (2020) · Cancers · doi:10.3390/cancers13010038 · Cited by 29
“NCT01865617 LBCL, FL, MCL 32 FMC63 IgG4 CD28 41BB CD3ζ lentivirus 2 × 105–2 × 107/kg [37,38]”
BackgroundMethodInfluentialAbken, H. (2021) · Human Gene Therapy · doi:10.1089/hum.2021.165 · Cited by 31
Gene editing to enhance the efficacy of cancer cell therapies
Murty, T., & Mackall, C. L. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.10.001 · Cited by 26
Zurko, J. C., Fenske, T. S., Johnson, B. D., Bucklan, D., Szabó, A., Xu, H., Chaney, K., Hamadani, M., Hari, P., & Shah, N. N. (2022) · American Journal of Hematology · doi:10.1002/ajh.26718 · Cited by 27
Tumor microenvironment and CAR‐T cell immunotherapy in B‐cell lymphoma
Cai, F., Zhang, J., Gao, H. Y., & Shen, H. (2023) · European Journal Of Haematology · doi:10.1111/ejh.14103 · Cited by 32
Recent advances in T‐cell immunotherapy for haematological malignancies
Rouce, R. H., Sharma, S., Huynh, M., & Heslop, H. E. (2016) · British Journal of Haematology · doi:10.1111/bjh.14470 · Cited by 26
CD19-targeted immunotherapies for treatment of patients with non-Hodgkin B-cell lymphomas
Watkins, M. P., & Bartlett, N. L. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2018.1492549 · Cited by 28
“directed CAR T cell with costimulatory signals provided by the 4-1BB (CD137) domain [59].”
BackgroundRelapse and Resistance to CAR-T Cells and Blinatumomab in Hematologic Malignancies
Jacoby, E. (2019) · Clinical Hematology International · doi:10.2991/chi.d.190219.001 · Cited by 27
Su, M., Chen, L., Xie, L., Fleurie, A., Jonquieres, R., Cao, Q., Li, B., Liang, J. A., & Tang, Y. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1450173 · Cited by 32
Transcriptomic analysis of the innate immune response to in vitro transfection of plasmid DNA
Warga, E., Anderson, J. L., Tucker, M., Harris, E., & Elmer, J. J. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.11.025 · Cited by 30
Mata, M., & Gottschalk, S. M. (2019) · Drugs · doi:10.1007/s40265-019-01071-7 · Cited by 28
Chen, X., Li, X., Liu, Y., Zhang, Z., Zhang, X., Huang, J., Li, H., Li, F., Zhang, L., Li, L., et al. (2020) · Immunotherapy · doi:10.2217/imt-2020-0022 · Cited by 28
Immunobiology of chimeric antigen receptor T cells and novel designs
Walsh, Z. H., Yang, Y., & Kohler, M. E. (2019) · Immunological Reviews · doi:10.1111/imr.12794 · Cited by 28
Eichholz, K., Fukazawa, Y., Peterson, C. W., Haeseleer, F., Medina, M., Hoffmeister, S. T., Duell, D. M., Varco-Merth, B. D., Dross, S., Park, H., et al. (2024) · Journal of Clinical Investigation · doi:10.1172/jci169309 · Cited by 27
“No evidence of the neurological symptoms reported with anti-CD19 or anti-CD20 CAR T cells was noted (38, 40).”
Chimeric antigen receptor T-cells for B-cell malignancies
Lichtman, E. I., & Dotti, G. (2017) · Translational research · doi:10.1016/j.trsl.2017.06.011 · Cited by 25
Innovative strategies to advance CAR T cell therapy for solid tumors.
Huang, M., Jinniu, D., Gao, L., & Zhou, J. (2020) · PubMed Central · Cited by 39
Cytokine Drizzle—The Rationale for Abandoning “Cytokine Storm”
Stolarski, A. E., Kim, J., Zhang, Q., & Remick, D. G. (2021) · Shock · doi:10.1097/shk.0000000000001769 · Cited by 27
Immune checkpoint inhibitors and cellular treatment for lymphoma immunotherapy
Li, F., Chen, Y., Pang, M., Yang, P., & Jing, H. (2021) · Clinical & Experimental Immunology · doi:10.1111/cei.13592 · Cited by 25
Meng, Y., Deng, B., Rong, L., Li, C., Song, W., Ling, Z., Xu, J., Duan, J., Wang, Z., Chang, A. H., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.640166 · Cited by 25
Engineered T Cell Therapy for Gynecologic Malignancies: Challenges and Opportunities
Xu, Y., Jiang, J., Wang, Y., Wang, W., Li, H., Lai, W., Zhou, Z., Zhu, W., Xiang, Z., Wang, Z., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.725330 · Cited by 32
“Currently, mainstream cell preparation methods include the following steps: (1) obtaining frozen apheresis white blood cell (WBC) product from patients; (2) the selection and enrichment of T cells by corresponding selection beads; (3) activation of T cells via addition of stimulating cytokines like interleukin (IL) 2…”
BackgroundMethodInfluentialTransverse myelitis after anti‐CD19 directed CAR T cell therapy for relapsed large B cell lymphoma
Sheikh, S., Mokhtari, S., Silverman, J. A., Reid, K. M., Faramand, R. G., Davila, M. L., Franke, N., Locke, F. L., Jain, M. D., Wong, D., et al. (2021) · eJHaem · doi:10.1002/jha2.286 · Cited by 25
“Our patient presentedwithmultiple risk factors including young age, extensive tumor burden at relapse, and she received a CD28-costimulated CAR T cell product [10].”
BackgroundMaziarz, R., Diaz, A. H., Miklos, D., & Shah, N. (2022) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2022.08.002 · Cited by 24
The Multi-Purpose Tool of Tumor Immunotherapy: Gene-Engineered T Cells
Mo, Z., Du, P., Wang, G., & Wang, Y. (2017) · Journal of Cancer · doi:10.7150/jca.18681 · Cited by 25
Metadata
- Authors
- Turtle, C. J., Hanafi, L.-A., Berger, C., Hudecek, M., Pender, B., Robinson, E., Hawkins, R., Chaney, C., Cherian, S., Chen, X., Soma, L., Wood, B., Li, D., Heimfeld, S., Riddell, S. R., & Maloney, D. G.
- Affiliations
- University of Washington (US)
- Fred Hutch Cancer Center (US)
- Juno Therapeutics (United States) (US)
- Corresponding author
- Turtle, Cameron J.
- Riddell, Stanley R.
- Maloney, David G.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2016-09-07
- Volume
- 8
- Issue
- 355
- Pages
- 355ra116-355ra116
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC5045301
- OpenAlex
- W2509364267
- Semantic Scholar
- af93b35d4d1ed32f3de2e434b4049004928a60bc
- Cited by
- 1,016
- References
- 38
- Citations by year
- 2026: 37 · 2025: 60 · 2024: 101 · 2023: 78 · 2022: 113 · 2021: 120 · 2020: 153 · 2019: 139 · 2018: 121 · 2017: 85 · 2016: 6
- FWCI
- 63.01
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01 CA136551)
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK56465)
- NCI (P30 CA15704)
- Life Science Discovery Fund
- Bezos Family Foundation
- Juno Therapeutics
- Topics
- Health Sciences › Medicine › Oncology › CAR-T cell therapy research
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- CAR T-cell therapy, non-Hodgkin lymphoma, B-cell lymphoma, CD4/CD8 ratio, lymphocyte depletion, cyclophosphamide, fludarabine, cytokine release syndrome, neurotoxicity, serum biomarkers, CAR T cell persistence, relapsed/refractory lymphoma
- MeSH terms
- Adult, Aged, Cyclophosphamide, Female, Humans, Immunotherapy, Lymphocyte Depletion, Lymphoma, Non-Hodgkin, Male, Middle Aged, Receptors, Antigen, T-Cell, Syndrome, Biomarkers, Tumor, Vidarabine, CD4-Positive T-Lymphocytes, Lymphocyte Subsets, Treatment Outcome, CD8-Positive T-Lymphocytes, Transgenes, Cell Proliferation, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.